Serveur d'exploration Tocilizumab - Analysis (France)

Index « Auteurs » - entrée « X. Le Loët »
Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.
X. Le Loet < X. Le Loët < X. Li  Facettes :

List of bibliographic references

Number of relevant bibliographic references: 6.
Ident.Authors (with country if any)Title
000369 (2015) A-P Trouvin ; S. Jacquot [France] ; S. Grigioni [France] ; E. Curis [France] ; I. Dedreux [France] ; A. Roucheux [France] ; H. Boulard ; O. Vittecoq [France] ; X. Le Loët ; O. Boyer [France] ; V. Goëb [France]Usefulness of monitoring of B cell depletion in rituximab-treated rheumatoid arthritis patients in order to predict clinical relapse: a prospective observational study
000531 (2013) A. Frazier-Mironer [France] ; A. Cantagrel [France] ; B. Combe [France] ; V. Deschamps ; M. Dougados [France] ; R.-M. Flipo ; I. Logeart ; X. Mariette ; T. Schaeverbeke ; J. Sibilia [France] ; X. Le Loët [France]THU0173 Retention Rates of Adalimumab, Etanercept and Infliximab as First and Second-Line Biologic Therapy in Patients with Rheumatoid Arthritis in Daily Practice: The Maintain Study
000561 (2013) J. Sellam [France] ; S. Rouanet ; H. Hendel-Chavez ; S. Marion-Thore [France] ; C. Miceli-Richard ; B. Combe [France] ; J. Sibilia [France] ; X. Le Loët ; J. Tebib ; G. Chiocchia [France] ; R. Jourdan ; M. Dougados [France] ; Y. Taoufik ; X. MarietteFRI0247 Serum level of interleukin 33, a novel independent predictive biomarker of clinical response to rituximab in rheumatoid arthritis: results from the smart trial
000562 (2013) J. H. Salmon ; P. Ravaud [France] ; T. Bardin ; P. Cacoub [France] ; A. Cantagruel [France] ; B. Combe [France] ; M. Dougados [France] ; R.-M. Flipo ; B. Godeau ; L. Guillevin [France] ; X. Le Loët ; E. Hachulla ; T. Schaeverbeke ; J. Sibilia [France] ; I. Pane [France] ; G. Baron ; X. Mariette [France] ; J.-E. Gottenberg [France]FRI0246 Serious infusion-related reactions after rituximab in patients with rheumatoid arthritis: data from the autoimmunity and rituximab registry
000627 (2012) J E Gottenberg [France] ; P. Ravaud [France] ; A. Cantagrel [France] ; B. Combe [France] ; R M Flipo [France] ; T. Schaeverbeke [France] ; E. Houvenagel [France] ; P. Gaudin [France] ; D. Loeuille [France] ; S. Rist [France] ; M. Dougados [France] ; J. Sibilia [France] ; X. Le Loët [France] ; C. Marcelli [France] ; T. Bardin [France] ; I. Pane [France] ; G. Baron [France] ; X. Mariette [France]Positivity for anti-cyclic citrullinated peptide is associated with a better response to abatacept: data from the ‘Orencia and Rheumatoid Arthritis’ registry
000628 (2012) A. Ruyssen-Witrand [France] ; S. Rouanet [France] ; B. Combe [France] ; M. Dougados [France] ; X. Le Loët [France] ; J. Sibilia [France] ; J. Tebib [France] ; X. Mariette [France] ; A. Constantin [France]Fcγ receptor type IIIA polymorphism influences treatment outcomes in patients with rheumatoid arthritis treated with rituximab

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/TocilizumabV1/Data/France/Analysis
HfdIndexSelect -h $EXPLOR_AREA/Data/France/Analysis/Author.i -k "X. Le Loët" 
HfdIndexSelect -h $EXPLOR_AREA/Data/France/Analysis/Author.i  \
                -Sk "X. Le Loët" \
         | HfdSelect -Kh $EXPLOR_AREA/Data/France/Analysis/biblio.hfd 

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    TocilizumabV1
   |flux=    France
   |étape=   Analysis
   |type=    indexItem
   |index=    Author.i
   |clé=    X. Le Loët
}}

Wicri

This area was generated with Dilib version V0.6.34.
Data generation: Fri May 22 09:34:00 2020. Site generation: Sun Mar 28 09:01:19 2021